ClinicalTrials.gg

Program

zolbetuximab

Also written as “Zolbetuximab”, “IMAB362” and “Claudiximab”.

Its studies are mostly in Adenocarcinoma · Stomach Neoplasms · Pancreatic Neoplasms · Adenocarcinoma Of Esophagus, led by Astellas Pharma.

Furthest: phase 4, since Sep 15, 202612 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma127 open or runningphase 4since Sep 15, 2026May 18, 2009Dec 31, 2026phase 1 · NCT06396091

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2009First study: phase 1 study in Solid TumorsFirst studyNCT00909025 · 15 enrolled · Germany, Latvia
  2. Sep 6, 2010Phase 2 study in Solid TumorsNCT01197885 · 54 enrolled · Bulgaria, Germany, Latvia and more
  3. Jun 19, 2012Phase 2 study in CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionNCT01630083 · 252 enrolled · Bulgaria, Czechia, Germany and more
  4. Mar 29, 2018Phase 2 study in Stomach NeoplasmsNCT03505320 · 143 enrolled · United States, France, Italy and more
  5. Apr 12, 2018Phase 3 study in AdenocarcinomaNCT03504397 · 565 enrolled · United States, Australia, Belgium and more
  6. May 6, 2018No phase study in Stomach NeoplasmsNCT03528629 · 18 enrolled · Japan
  7. Aug 24, 2018Phase 3 study in AdenocarcinomaNCT03653507 · 507 enrolled · United States, Argentina, Canada and more
  8. Jan 23, 2019Phase 2 study in Pancreatic NeoplasmsNCT03816163 · 393 enrolled · United States, Australia, Brazil and more
  9. Sep 10, 2019Phase 1 study in AdenocarcinomaNCT04086758 · 12 enrolled · China
  10. Apr 30, 2024Phase 1 study in Metastatic Pancreatic AdenocarcinomaNCT06396091 · 12 enrolled · United States
  11. Mar 27, 2025Phase 3 study in AdenocarcinomaNCT06901531 · 500 planned · United States, Australia, Belgium and more
  12. Sep 15, 2026Phase 4 study in AdenocarcinomaNCT07829757 · 50 planned
  13. Oct 16, 2026Primary completion moved from 2026-07-31 to 2026-12-31Date moved laterphase 1 · +5 months · NCT06396091

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Metastatic Pancreatic AdenocarcinomaNCT06396091
  2. Jun 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT03505320
  3. Sep 30, 2028Primary completion: phase 3 study in AdenocarcinomaNCT06901531
  4. Jul 31, 2029Primary completion: phase 4 study in AdenocarcinomaNCT07829757

TargetBeta

CLDN18 →read by rule
“A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule
“Claudin-18 binding agent”ChEMBL 37, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07829757Adenocarcinoma4Not yet recruitingJul 31, 202950
NCT06901531Adenocarcinoma · United States, Australia, Belgium and more3RecruitingSep 30, 2028500
NCT06396091Metastatic Pancreatic Adenocarcinoma · United States1Active, not recruitingDec 31, 202612
NCT04086758Adenocarcinoma · China1CompletedJan 22, 202112
NCT03816163Pancreatic Neoplasms · United States, Australia, Brazil and more2Active, not recruitingOct 31, 2026393
NCT03653507Adenocarcinoma · United States, Argentina, Canada and more3Active, not recruitingOct 25, 2022507
NCT03528629Stomach Neoplasms · Japan–CompletedJun 9, 202018
NCT03504397Adenocarcinoma · United States, Australia, Belgium and more3Active, not recruitingSep 9, 2022565
NCT03505320Stomach Neoplasms · United States, France, Italy and more2Active, not recruitingJun 30, 2027143
NCT01630083CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction · Bulgaria, Czechia, Germany and more2CompletedJan 31, 2019252
NCT01197885Solid Tumors · Bulgaria, Germany, Latvia and more2CompletedAug 13, 201554
NCT00909025Solid Tumors · Germany, Latvia1CompletedMay 31, 201015

How it is read

Names in the registry

  • “zolbetuximab”, 8 entries
  • “Zolbetuximab”, 2 entries
  • “IMAB362”, 1 entry
  • “Claudiximab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.